PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21474579-0	2011	HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.	KW 2449	72-79	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	47-54
33819469-0	2021	The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis.	KW 2449	35-42	receptor interacting serine/threonine kinase 1	Homo sapiens	101-106
33819469-5	2021	Mechanistic studies indicated that KW-2449 directly inhibited RIPK1 kinase activity to block necroptosis.	KW 2449	35-42	receptor interacting serine/threonine kinase 1	Homo sapiens	62-67
33819469-7	2021	Taken together, our study shows that KW-2449 is a novel necroptosis inhibitor by targeting RIPK1 kinase activity and has great clinic potential for the treatment of cisplatin-induced nephrotoxicity.	KW 2449	37-44	receptor interacting serine/threonine kinase 1	Homo sapiens	91-96
33155932-10	2021	KW-2449 also decreased TNF-alpha, IL-6, CCL-2 inflammatory cytokines and MMP-2 in both brain mRNA expressions and serum levels of EAE mice.	KW 2449	0-7	tumor necrosis factor	Mus musculus	23-32
33155932-10	2021	KW-2449 also decreased TNF-alpha, IL-6, CCL-2 inflammatory cytokines and MMP-2 in both brain mRNA expressions and serum levels of EAE mice.	KW 2449	0-7	interleukin 6	Mus musculus	34-38
33155932-10	2021	KW-2449 also decreased TNF-alpha, IL-6, CCL-2 inflammatory cytokines and MMP-2 in both brain mRNA expressions and serum levels of EAE mice.	KW 2449	0-7	chemokine (C-C motif) ligand 2	Mus musculus	40-45
33155932-10	2021	KW-2449 also decreased TNF-alpha, IL-6, CCL-2 inflammatory cytokines and MMP-2 in both brain mRNA expressions and serum levels of EAE mice.	KW 2449	0-7	matrix metallopeptidase 2	Mus musculus	73-78
31366578-8	2019	Injection of KEEC KW-2449 or piperine in Mecp2 mutant mice ameliorated disease-associated respiratory and locomotion phenotypes.	KW 2449	18-25	methyl CpG binding protein 2	Mus musculus	41-46
29451686-0	2018	An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins.	KW 2449	119-126	aldehyde oxidase 1	Homo sapiens	167-183
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	28-35	monoamine oxidase B	Homo sapiens	219-238
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	28-35	monoamine oxidase B	Homo sapiens	240-245
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	28-35	aldehyde oxidase 1	Homo sapiens	301-317
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	28-35	aldehyde oxidase 1	Homo sapiens	241-243
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	37-90	monoamine oxidase B	Homo sapiens	219-238
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	37-90	monoamine oxidase B	Homo sapiens	240-245
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	37-90	aldehyde oxidase 1	Homo sapiens	301-317
29451686-1	2018	We previously reported that KW-2449, (E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor developed for the treatment of leukemia patients, was oxidized to an iminium ion intermediate by monoamine oxidase B (MAO-B) and then converted to its oxo-piperazine form (M1) by aldehyde oxidase (AO).	KW 2449	37-90	aldehyde oxidase 1	Homo sapiens	241-243
29451686-6	2018	These findings strongly suggest that the iminium ion metabolite of KW-2449 is highly reactive in inhibiting AO irreversibly and binding to endogenous macromolecules covalently.	KW 2449	67-74	aldehyde oxidase 1	Homo sapiens	108-110
28751116-0	2017	Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human.	KW 2449	59-66	monoamine oxidase B	Homo sapiens	0-19
28751116-0	2017	Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human.	KW 2449	59-66	aldehyde oxidase 1	Homo sapiens	90-106
28751116-3	2017	An inhibition study suggested that monoamine oxidase-B (MAO-B) oxidizes KW-2449 to an iminium (intermediate) and aldehyde oxidase (AO) then metabolizes the intermediate to M1.	KW 2449	72-79	monoamine oxidase B	Homo sapiens	35-54
28751116-3	2017	An inhibition study suggested that monoamine oxidase-B (MAO-B) oxidizes KW-2449 to an iminium (intermediate) and aldehyde oxidase (AO) then metabolizes the intermediate to M1.	KW 2449	72-79	monoamine oxidase B	Homo sapiens	56-61
28751116-4	2017	The conversion of KW-2449 to the iminium (intermediate) by MAO-B was confirmed by the formation of its cyanide adduct.	KW 2449	18-25	monoamine oxidase B	Homo sapiens	59-64
21474579-0	2011	HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.	KW 2449	72-79	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	116-123
21263155-5	2011	In vitro, exogenous FL at concentrations similar to those observed in patients mitigated FLT3 inhibition and cytotoxicity for each of 5 different FLT3 inhibitors (lestaurtinib, midostaurin, sorafenib, KW-2449, and AC220).	KW 2449	201-208	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	20-22
19029442-0	2009	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.	KW 2449	46-53	fms related receptor tyrosine kinase 3	Homo sapiens	31-35
19029442-4	2009	KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity in Molm14 cells (which harbor an FLT3/ITD mutation).	KW 2449	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	109-113
19541823-0	2009	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.	KW 2449	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	85-89
19541823-0	2009	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.	KW 2449	0-7	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	108-124
19541823-1	2009	KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.	KW 2449	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	36-40
19541823-1	2009	KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.	KW 2449	0-7	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	42-45
19541823-1	2009	KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.	KW 2449	0-7	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	47-50
19541823-3	2009	KW-2449 showed the potent growth inhibitory effects on leukemia cells with FLT3 mutations by inhibition of the FLT3 kinase, resulting in the down-regulation of phosphorylated-FLT3/STAT5, G(1) arrest, and apoptosis.	KW 2449	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	75-79
19541823-3	2009	KW-2449 showed the potent growth inhibitory effects on leukemia cells with FLT3 mutations by inhibition of the FLT3 kinase, resulting in the down-regulation of phosphorylated-FLT3/STAT5, G(1) arrest, and apoptosis.	KW 2449	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	111-115
19541823-3	2009	KW-2449 showed the potent growth inhibitory effects on leukemia cells with FLT3 mutations by inhibition of the FLT3 kinase, resulting in the down-regulation of phosphorylated-FLT3/STAT5, G(1) arrest, and apoptosis.	KW 2449	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	111-115
19541823-3	2009	KW-2449 showed the potent growth inhibitory effects on leukemia cells with FLT3 mutations by inhibition of the FLT3 kinase, resulting in the down-regulation of phosphorylated-FLT3/STAT5, G(1) arrest, and apoptosis.	KW 2449	0-7	signal transducer and activator of transcription 5A	Homo sapiens	180-185
19541823-4	2009	Oral administration of KW-2449 showed dose-dependent and significant tumor growth inhibition in FLT3-mutated xenograft model with minimum bone marrow suppression.	KW 2449	23-30	fms related receptor tyrosine kinase 3	Homo sapiens	96-100